#USA #CFO #LabConnect #Johnson City #Mitch Blumenfeld

LabConnect Introduces Mitch Blumenfeld as CFO

LabConnect has officially announced the appointment of Mitch Blumenfeld as the Chief Financial Officer (CFO), effective August 4, 2025. Mitch comes aboard with an extensive background as CFO, having worked with several high-growth enterprises across various sectors, including pharmaceutical services, wholesale pharmaceuticals, and diversified manufacturing and consumer goods. With more than three decades of leadership experience, he brings valuable expertise in financial management and strategic business development.

Prior to joining LabConnect, Blumenfeld served as CFO for Network Partners Group, a global consultancy in the life sciences and medical devices sector. This organization provides essential services including quality assurance, regulatory affairs, project management, packaging engineering, and labeling. His previous roles also include being CFO at Signant Health, a global leader in clinical research software and services, and at PCI Pharma Services, which specializes in development and manufacturing. Additionally, Blumenfeld held various leadership positions at AmerisourceBergen Corporation and across multiple business sectors within General Electric.

Blumenfeld holds a Master’s degree in Computer Science and Applications from Virginia Tech, as well as a Bachelor's degree in Computer Science and Engineering from Bucknell University.

Wes Wheeler, CEO of LabConnect, expressed his enthusiasm about Blumenfeld's arrival: "I am thrilled to welcome Mitch to LabConnect and our leadership team. I am confident that his leadership skills and expertise will play a critical role in driving LabConnect's profitable growth and achieving operational excellence across the company while advancing our capital allocation priorities."

In his role as CFO of LabConnect, Blumenfeld will lead the global finance organization, overseeing Business Finance, Accounting, Treasury, Financial Planning and Analysis, Taxes, and Investor Relations.

"I am excited to join LabConnect at such a pivotal moment," stated Blumenfeld. "The company is redefining global central laboratory services, and I look forward to being part of this journey."

About LabConnect

LabConnect is recognized as the world's most agile partner for central laboratory solutions, providing technology-enabled, customizable, orchestrated, and scalable support services for clinical trials of all sizes and complexities. With over 20 years of experience and more than 2,000 clinical studies conducted in 93 countries, LabConnect is a reliable ally for biotechnology, pharmaceutical, and clinical research organizations.

Thanks to its advanced operational processes and strategic alliances with leading laboratories worldwide, LabConnect is uniquely positioned to provide access to the latest innovations and automation. The company excels in delivering an outstanding range of central laboratory solutions, including customized lab kits, advanced sample tracking, integrated logistics, globally standardized sample processing, and a leading test menu with over 20,000 validated tests, as well as comprehensive support for radiopharmaceuticals and a next-generation biorepository.

LabConnect’s scientific experts assist both preclinical and clinical studies with scientific project management, bioanalytical and biological sample management, biomarker strategies, and logistics solutions. The company stands out for its exceptional data management, integrating complex datasets from a variety of sources into a cohesive, submission-ready dataset.

For more information, follow LabConnect on LinkedIn or visit www.labconnect.com.